Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income: 2015-2025

Historic Other Non Operating Income for Sunshine Biopharma (SBFM) over the last 9 years, with Sep 2025 value amounting to $253.

  • Sunshine Biopharma's Other Non Operating Income fell 98.33% to $253 in Q3 2025 from the same period last year, while for Sep 2025 it was -$337,359, marking a year-over-year decrease of 214.02%. This contributed to the annual value of -$44,082 for FY2024, which is 17892.65% down from last year.
  • Per Sunshine Biopharma's latest filing, its Other Non Operating Income stood at $253 for Q3 2025, which was down 86.96% from $1,940 recorded in Q2 2025.
  • Sunshine Biopharma's Other Non Operating Income's 5-year high stood at $286,535 during Q2 2024, with a 5-year trough of -$340,003 in Q4 2024.
  • Its 3-year average for Other Non Operating Income is -$3,789, with a median of $40 in 2023.
  • Data for Sunshine Biopharma's Other Non Operating Income shows a peak YoY increase of 109,883.52% (in 2024) and a maximum YoY decrease of 871,702.56% (in 2024) over the last 5 years.
  • Sunshine Biopharma's Other Non Operating Income (Quarterly) stood at -$7,909 in 2021, then crashed by 99.67% to $25 in 2022, then spiked by 60.00% to -$39 in 2023, then tumbled by 871,702.56% to -$340,003 in 2024, then slumped by 98.33% to $253 in 2025.
  • Its Other Non Operating Income stands at $253 for Q3 2025, versus $1,940 for Q2 2025 and $451 for Q1 2025.